Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-03-22
2005-03-22
Wehbe, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C435S320100, C536S023100
Reexamination Certificate
active
06869936
ABSTRACT:
The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for fibroblast-like or macrophage-like cells, preferably synoviocytes. In one aspect the nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably, the virus capsid is an adenovirus capsid. Preferably, the adenovirus is a subgroup B adenovirus, preferably adenovirus 16. Preferably, the tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, preferably joint related diseases.
REFERENCES:
patent: 5585254 (1996-12-01), Maxwell et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5861290 (1999-01-01), Goldsmith et al.
patent: 6329190 (2001-12-01), Wickham et al.
patent: 6455314 (2002-09-01), Wickham et al.
patent: 9700326 (1997-01-01), None
Shang et al, J Immunol 1998;160:467-74.*
Lazarovits et al, J Immunol 1993;151:6482-9.*
Bowie et al, Science 1990 Mar.; 247:1306-10.*
Mei et al, Virol 1998;240:254-66.*
Rudinger, Peptide Hormones 1976; Jun.;pp. 1-7.*
Robbins et al, Pharmacol Ther 1998;80:35-47.*
Verma et al, Nature 1997;389;239-42.*
Miller et al, 1995, FASEB J., vol. 9, pp. 190-199.*
Makrides et al , Protein Exp Pur 1999;17:183-202.*
Deonarain, 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.*
Russell et al, Nat Genet 1998 Apr.; 18:325-30.*
Boucher et al, J Clin Invest 1999 Feb.; 103:441-5.*
Zink et al, Gene Ther Mol Biol 2001 Jan.;6:1-24.*
Stevenson et al (J Virol 1997;6:4782-90.*
Crystal et al., Transfer of Gene to Human: Early Lessons and Obstacles to Success, 1995, Science, vol. 270, pp. 404-410.
Eck et al., Gene-Based Therapy, 1996 Goodman & Gilman's, pp. 77-101.
Gall et al., Journal of Virology, 1996, pp. 2116-2123, vol. 70.
Guzman et al., PNAS, 1994, pp. 10732-10736, vol. 91.
Kaye et al., A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, Sep. 1990, Proc. Natl. Acad. Sci., pp. 6922-6926, vol. 87.
Lusky et al., Journal of Virology, 1998, pp. 2022-2032, vol. 72.
Su, et al., A Genetically Modified Adenoviral Vector Exhibits Enhanced Gene Transfer of Human Smooth Muscle Cells, Journal of Vascular Research 2001, pp. 471-478, vol. 38.
Wickham et al., Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Protein, Nov. 1997, Journal of Virology, pp. 8221-8229, vol. 71, No. 11.
Wilson et al., Adenovirus Vectors in the Development of Gene Therapy, 1999, Friedman, T ed. CSHL Press, Cold Spring Harbor, New York.
Bout Abraham
Havenga Menzo Jans Emco
Schouten Govert J.
Vogels Ronald
Crucell Holland B.V.
Li Q. Janice
TraskBritt
Wehbe Anne M.
LandOfFree
Means and methods for fibroblast-like or macrophage-like... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means and methods for fibroblast-like or macrophage-like..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means and methods for fibroblast-like or macrophage-like... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387501